Article

Venture capitalists back device firm incubator

Menlo Park, CA?Three venture capital firms have promised $2.4 million in seed funding to start ForSight Labs, a new incubator of firms to launch ophthalmic medical device technologies. Representatives of Morgenthaler Ventures, Split Rock Partners, and Versant Ventures will also take seats on the ForSight Labs board of directors.

Menlo Park, CA-Three venture capital firms have promised $2.4 million in seed funding to start ForSight Labs, a new incubator of firms to launch ophthalmic medical device technologies. Representatives of Morgenthaler Ventures, Split Rock Partners, and Versant Ventures will also take seats on the ForSight Labs board of directors.

The incubator is led by renowned inventor and ophthalmology professor Eugene de Juan, MD, and The Foundry, an incubator responsible for developing nine medical device companies, most of which focus on cardiovascular therapies.

ForSight aims to build companies with ophthalmic products for glaucoma, cataracts, and age-related macular degeneration, as well as drug-delivery technology.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.